TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24169120

Group type: EXPERIMENTAL
Intervention: DermaVir (0.1 or 0.4 mg of plasmid DNA at weeks 1, 7, and 13; 0.8 mg at weeks 0, 1, 6, 7, 12, and 13)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: DermaVir (intermediate-dose)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 22023876

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19916848

Group type: EXPERIMENTAL
Intervention: Quetiapine (58.3 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 17030114

Group type: EXPERIMENTAL
Intervention: High calcium skim milk with added phylloquinone (80 microg/d)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: High calcium skim milk without added phylloquinone (1000 mg/d of extra calcium)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 82
Study: 15098126

Group type: EXPERIMENTAL
Intervention: Total-Body Mass (TBM) protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fat-Free Mass (FFM) protocol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both TBM and FFM protocols
Number of subjects: 0
Study: 11345281

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 9408414

Group type: EXPERIMENTAL
Intervention: Minilaparotomy (ML)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Conventional Approach (CA)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Minilaparotomy (ML) and Conventional Approach (CA)
Number of subjects: 62
Study: 8431122

Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (DDAVP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desmopressin plus warfarin therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 0
Study: 3315582

Group type: EXPERIMENTAL
Intervention: APSAC 30U
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 29476713

Group type: EXPERIMENTAL
Intervention: Dynamic neuromuscular stabilization (DNS)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional core stabilization
Number of subjects: 28
Study: 27323348

Group type: EXPERIMENTAL
Intervention: NAC arm (four cycles of TC, IDS, and four cycles of TC)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Standard arm (PDS followed by eight cycles of TC)
Number of subjects: 301
Study: 25591516

Group type: EXPERIMENTAL
Intervention: Cytoflavin for 10 days
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Cytoflavin for 20 days
Number of subjects: 185

Group type: COMPARATOR
Intervention: Ascorbic acid (Control)
Number of subjects: 185
Study: 22459697

Group type: EXPERIMENTAL
Intervention: 4 weeks of assistance training followed by 4 weeks of resistance training
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 4 weeks of resistance training followed by 4 weeks of assistance training
Number of subjects: 10
Study: 20810214

Group type: EXPERIMENTAL
Intervention: etoricoxib 60 mg
Number of subjects: 639

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 639
Study: 18704485

Group type: EXPERIMENTAL
Intervention: Focused parathyroidectomy (FP)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Bilateral neck exploration (BNE)
Number of subjects: 48
Study: 15969313

Group type: EXPERIMENTAL
Intervention: Participation in RCTs by geriatricians
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perception of necessity for RCTs in very elderly subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contact regarding participation in RCTs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Difficulties in developing RCTs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Obstacles in RCT development
Number of subjects: 0
Study: 11572288

Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond 2V
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Etch & Prime 3.0
Number of subjects: 60

Group type: COMPARATOR
Intervention: Prime & Bond NT (Control)
Number of subjects: 60
Study: 9773802

Group type: EXPERIMENTAL
Intervention: Oral ondansetron (24 mg) plus dexamethasone (12 mg)
Number of subjects: 530

Group type: COMPARATOR
Intervention: i.v. ondansetron (8 mg) plus dexamethasone (20 mg)
Number of subjects: 530
Study: 7824325

Group type: EXPERIMENTAL
Intervention: 15 mg/kg intravenous dose of vancomycin over 90 min upon anesthesia (Group 1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 15 mg/kg intravenous dose of vancomycin followed by a second 7.5 mg/kg intravenous dose over 30 min (Group 2)
Number of subjects: 20
Study: 2975552

Group type: EXPERIMENTAL
Intervention: Health counselling with home visit by a health visitor
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine advice on health hazards of smoking
Number of subjects: 60
Study: 31818522

Group type: EXPERIMENTAL
Intervention: Training in shared decision-making
Number of subjects: 311
Study: 29952807

Group type: EXPERIMENTAL
Intervention: MINT protocol (32 × 5-sec intermittent grips at maximal intensity with 5-sec rest between sets)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ZONA protocol (4 × 2-min sustained grips at 30% moderate intensity with 1-min rest between sets)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-exercise control
Number of subjects: 20
Study: 27682331

Group type: EXPERIMENTAL
Intervention: PSALTI intervention (physiotherapy and speech and language therapy) consisting of education, laryngeal hygiene and hydration, cough suppression techniques, breathing exercises and psychoeducational counselling.
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: PSALTI intervention (physiotherapy and speech and language therapy).
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control intervention (healthy lifestyle advice).
Number of subjects: 75
Study: 24069469

Group type: EXPERIMENTAL
Intervention: Health hygiene education intervention including an initial one hour in-class activity and 30-minute refresher activities every two weeks for four months.
Number of subjects: 1089

Group type: EXPERIMENTAL
Intervention: Single-dose albendazole (400 mg) treatment followed by health hygiene education intervention.
Number of subjects: 1089

Group type: COMPARATOR
Intervention: Control group with no health hygiene education intervention after deworming.
Number of subjects: 1089
Study: 19755572

Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg single dose)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 16443788

Group type: EXPERIMENTAL
Intervention: Insulin infusion at rest
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Insulin infusion during adenosine-induced hyperemia
Number of subjects: 43

Group type: COMPARATOR
Intervention: Fasting state
Number of subjects: 43
Study: 14735177

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel plus cisplatin (PC) - Paclitaxel 66 mg/m² i.v. on days 1, 8, and 15; Cisplatin 60 mg/m² i.v. on day 15.
Number of subjects: 140

Group type: COMPARATOR
Intervention: Vinorelbine plus cisplatin (VC) - Vinorelbine 23 mg/m² i.v. on days 1, 8, and 15; Cisplatin 60 mg/m² i.v. on day 15.
Number of subjects: 140
Study: 11816531

Group type: EXPERIMENTAL
Intervention: 200 micrograms of prostaglandin E1 (misoprostol) intravaginal after IUI
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (no misoprostol)
Number of subjects: 59
Study: 9441769

Group type: EXPERIMENTAL
Intervention: Early oral intake (clear liquid diet on postoperative day 1, regular diet after tolerating 500 cc)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Traditional dietary advancement (oral intake initiated after bowel function is documented)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Early oral intake
Number of subjects: 96

Group type: COMPARATOR
Intervention: Traditional dietary advancement
Number of subjects: 96
Study: 7898991

Group type: EXPERIMENTAL
Intervention: Soy formula with native phytic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soy formula with zero phytic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Native phytate-containing formula with increased ascorbic acid (Fe:ascorbic acid molar ratio from 1:2.1 to 1:4.2)
Number of subjects: 0
Study: 3281603

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA) at an initial dosage of 5 mg/kg daily
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 31501801

Group type: EXPERIMENTAL
Intervention: Smartphone-based CASA system
Number of subjects: 28
Study: 27454218

Group type: EXPERIMENTAL
Intervention: Heat applied immediately after exercise
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Heat applied 24 hours after exercise
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no heat applied)
Number of subjects: 60
Study: 26112397

Group type: EXPERIMENTAL
Intervention: Effective Parenting Programme (EPP)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 412
Study: 23608654

Group type: EXPERIMENTAL
Intervention: Riboflavin (1.6 mg/d) for 16 weeks
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 21691817

Group type: EXPERIMENTAL
Intervention: High Dose Vitamin D2 supplementation (HDD) 50,000 IU capsules weekly for 8 weeks then monthly for 4 months (Stratum A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High Dose Vitamin D2 supplementation (HDD) for 16 weeks and then monthly for 2 months (Stratum B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (Stratum A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (Stratum B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High Dose Vitamin D2 supplementation (HDD)
Number of subjects: 60
Study: 18927482

Group type: EXPERIMENTAL
Intervention: Silver nylon dressing (n = 365)
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Standard gauze dressing (control, n = 1,235)
Number of subjects: 1600
Study: 22813231

Group type: EXPERIMENTAL
Intervention: Stimulation therapy
Number of subjects: 187

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study: 16274602

Group type: EXPERIMENTAL
Intervention: Modified ethylene glycol‐based vitrification protocol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional slow‐freezing protocol
Number of subjects: 40
Study: 12860833

Group type: EXPERIMENTAL
Intervention: Aldosterone (500 ng/min)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Aldosterone with L‐NMMA
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Aldosterone with sodium nitroprusside
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Aldosterone with phenylephrine
Number of subjects: 48
Study: 9869019

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (30 mg)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Amlodipine (5 mg)
Number of subjects: 356
Study: 7620108

Group type: EXPERIMENTAL
Intervention: 10 micrograms SCI‐B‐VAC
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: 20 micrograms Engerix‐B
Number of subjects: 295

Group type: COMPARATOR
Intervention: 10 micrograms B‐Hepavac‐II
Number of subjects: 295
Study: 2570582

Group type: EXPERIMENTAL
Intervention: Ridazolol alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Molsidomine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of Ridazolol and Molsidomine
Number of subjects: 12
Study: 1249694

Group type: EXPERIMENTAL
Intervention: Rocking waterbeds and auditory stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29708058

Group type: EXPERIMENTAL
Intervention: Neck posture monitoring using an inclinometer during 2 hours of work time
Number of subjects: 40
Study: 31748290

Group type: EXPERIMENTAL
Intervention: Multidisciplinary, customised lifestyle intervention stimulating physical activity, healthy diet, and smoking cessation (if applicable).
Number of subjects: 112
Study: 29325336

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.08%
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.10%
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.12%
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.14%
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ropivacaine (all doses)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 80
Study: 25307476

Group type: EXPERIMENTAL
Intervention: skintrek cream PUVA
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: skintrek bath PUVA
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: skintrek UVB
Number of subjects: 28

Group type: COMPARATOR
Intervention: conventional bath PUVA
Number of subjects: 28

Group type: COMPARATOR
Intervention: NB-UVB
Number of subjects: 28
Study: 23349741

Group type: EXPERIMENTAL
Intervention: Quinine
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DHAPQ)
Number of subjects: 220
Study: 21862301

Group type: EXPERIMENTAL
Intervention: re-esterified omega-3 fatty acid triacylglycerols (n3-FA-rTAGs)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: ethyl-esters (n3-FA-EEs)
Number of subjects: 150

Group type: COMPARATOR
Intervention: corn oil (placebo)
Number of subjects: 150
Study: 18640342

Group type: EXPERIMENTAL
Intervention: Bioresorbable barrier film
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 103
Study: 16816861

Group type: EXPERIMENTAL
Intervention: PEG-INF alpha-2a (180 microg or 135 microg/week) and RBV 900 mg/d
Number of subjects: 89

Group type: COMPARATOR
Intervention: IFNalpha-2a (5 MIU/qod) and RBV 900 mg/d
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: PEG-INF alpha-2a
Number of subjects: 89

Group type: COMPARATOR
Intervention: IFNalpha-2a
Number of subjects: 89
Study: 12614707

Group type: EXPERIMENTAL
Intervention: Group format of the 'Women take PRIDE' heart disease management program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self‐Directed format of the 'Women take PRIDE' heart disease management program
Number of subjects: 0
Study: 11145354

Group type: EXPERIMENTAL
Intervention: Single-bottle bonding agents
Number of subjects: 1058

Group type: COMPARATOR
Intervention: Scotchbond Multi-Purpose
Number of subjects: 1058

Group type: COMPARATOR
Intervention: Tenure primer
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: Early eruption stage
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: Behavior
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: Salivary problems
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: Visually apparent variations in enamel
Number of subjects: 1058
Study: 8885118

Group type: EXPERIMENTAL
Intervention: 4 mg/kg gentamicin loading dose
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2.5 mg/kg gentamicin standard dose
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Two SGC after the first dose
Number of subjects: 40
Study: 1296606

Group type: EXPERIMENTAL
Intervention: rifampin/trimethoprim
Number of subjects: 243

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 243
Study: 3972525

Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 435

Group type: COMPARATOR
Intervention: diatrizoate
Number of subjects: 435
Study: 29967332

Group type: EXPERIMENTAL
Intervention: 0.5 ug/kg dexmedetomidine + 100 μg sufentanil + 300 μg dexmedetomidine (study group)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Normal saline + 100 μg sufentanil (control group)
Number of subjects: 208
Study: 28621259

Group type: EXPERIMENTAL
Intervention: Multifaceted podiatry intervention including footwear advice, footwear provision, foot orthoses, and foot- and ankle-strengthening exercises
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Multifaceted podiatry intervention
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1010
Study: 24420310

Group type: EXPERIMENTAL
Intervention: Gain-framed warnings on plain packs
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Pictorial warnings about lung disease and cancer
Number of subjects: 740

Group type: COMPARATOR
Intervention: Loss-framed warnings on plain packs
Number of subjects: 740
Study: 24113055

Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Number of subjects: 748

Group type: COMPARATOR
Intervention: 3-Dimensional Conformal Radiation Therapy (3D-CRT)
Number of subjects: 748
Study: 21039720

Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 18283247

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Heroin
Number of subjects: 117
Study: 16553636

Group type: EXPERIMENTAL
Intervention: Florida Probe (FP) (159 N/cm(2))
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Jonker Probe (JP) (153 N/cm(2))
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Brodontic Probe (BP) (255 N/cm(2))
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Manual Probe (MP)
Number of subjects: 12
Study: 12710219

Group type: EXPERIMENTAL
Intervention: Studying longer, 14-item DRM lists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Studying shorter DRM lists
Number of subjects: 0
Study: 11528574

Group type: EXPERIMENTAL
Intervention: Atovaquone-proguanil
Number of subjects: 976

Group type: COMPARATOR
Intervention: Mefloquine
Number of subjects: 976
Study: 9645716

Group type: EXPERIMENTAL
Intervention: Pre-enucleation radiation
Number of subjects: 1003

Group type: COMPARATOR
Intervention: Enucleation alone
Number of subjects: 1003
Study: 7948436

Group type: EXPERIMENTAL
Intervention: High-dose surfactant treatment (200 mg/kg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low-dose surfactant treatment (100 mg/kg)
Number of subjects: 15
Study: 3070473

Group type: EXPERIMENTAL
Intervention: Aerosolized salbutamol
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 31621832

Group type: EXPERIMENTAL
Intervention: CVac-chloroquine arm
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CVac-primaquine/chloroquine arm
Number of subjects: 36

Group type: COMPARATOR
Intervention: Infectivity controls
Number of subjects: 36
Study: 29277607

Group type: EXPERIMENTAL
Intervention: Mastic oleoresin (MO), 15g administered for three days through smoking the episiotomy wound
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Mastic oleoresin (MO)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control group (no MO treatment)
Number of subjects: 147
Study: 28914126

Group type: EXPERIMENTAL
Intervention: Patient navigation services
Number of subjects: 0
Study: 26261111

Group type: EXPERIMENTAL
Intervention: Natural frequency representation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Single-event probability format
Number of subjects: 200
Study: 23157691

Group type: EXPERIMENTAL
Intervention: Outcome Questionnaire 45 (OQ-45) with feedback
Number of subjects: 374

Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 374
Study: 21738098

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Pain clinic (PC) evaluation with or without treatment
Number of subjects: 158

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Pain clinic (PC)
Number of subjects: 158
Study: 18458035

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen plus EMLA
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (placebo cream) with nitrous oxide/oxygen
Number of subjects: 55
Study: 16449745

Group type: EXPERIMENTAL
Intervention: Therapeutic Touch (TT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mimic Therapeutic Touch (MT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 12958547

Group type: EXPERIMENTAL
Intervention: Warm intermittent blood cardioplegia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cold intermittent blood cardioplegia
Number of subjects: 40
Study: 10484801

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.2 mg/kg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Normal saline solution (control)
Number of subjects: 70
Study: 8564129

Group type: EXPERIMENTAL
Intervention: 2.5 mg rhDNase aerosol, twice a day for six consecutive days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 20
Study: 2021379

Group type: EXPERIMENTAL
Intervention: Multi-component behavioral treatment package (IBD education, progressive muscle relaxation, thermal biofeedback, cognitive coping strategies)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Symptom-monitoring (control condition)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Multi-component behavioral treatment package
Number of subjects: 21
Study: 6217892

Group type: EXPERIMENTAL
Intervention: Ionic contrast media of high osmolality
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonionic contrast media or ionic contrast media of low osmolality
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All contrast media used
Number of subjects: 40
Study: 29679478

Group type: EXPERIMENTAL
Intervention: bleselumab (0.1, 0.3, 1.0 or 3.0 mg/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: bleselumab (1.0 or 3.0 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 28662313

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CRT) with concurrent cisplatin followed by adjuvant cisplatin plus fluorouracil
Number of subjects: 348

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 348
Study: 26197975

Group type: EXPERIMENTAL
Intervention: Monosodium glutamate (MSG) ingestion (150 mg/kg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Glutamate (Glu) injection (0.5 M, 0.2 ml)
Number of subjects: 16

Group type: COMPARATOR
Intervention: NaCl (placebo) injection (0.9%, 0.2 ml)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pre-injection MSG ingestion
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Glu injections into the masseter muscle
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: MSG ingestion and Glu injection in the jaw muscles
Number of subjects: 16